Management Team

Dr. Oster

Wolfgang Oster, M.D., PhD.

Chief Executive Officer

Dr. Oster has had successful careers in academia, in the pharma/biotech corporate world and in the investment industry. He received board certifications for internal medicine, hematology, and oncology, and served as Adjunct Professor at the Brown Medical School and at the University of Freiburg, Germany. He is the author of more than 100 publications and a recipient of the Johann Georg Zimmermann Award for Cancer Research. As a C-level Executive he worked at Behringwerke/Hoechst, and later at US BioScience and NeoRx before joining PolyTechnos Venture Partners as Managing Partner. During his tenure as Executive, Board Member and Investor he oversaw multiple drug, diagnostic and medical device projects from earliest stages to market introduction in all relevant global markets. He was involved in the development and approval of widely recognized therapies in oncology and hematology indications, including hematopoietic growth factors, cytokines, monoclonal antibodies, cytotoxic and cytoprotective agents, methylation-based technologies for diagnostic purposes, as well as interventional technologies in neurology and cardiology. At US BioScience he was instrumental as Chief Medical Officer in the successful merger with Medimmune. At PolyTechnos he built a life science portfolio leading to five U.S. and European IPOs, including Devgen, Jerini, Addex, OMS, and Micrus, as well as trade sales (in some cases subsequent to IPO), including BiPar, Jerini and Micrus. Dr. Oster has also served on the Board of Directors at numerous companies, including as Chairman. Currently he is the CEO and Chairman of Oncoceutics, an oncology company he co-founded in 2009. He also serves as a guest lecturer at University of Pennsylvania’s Wharton School.

Lee Headshot

Lee Schalop, M.D.

Chief Operating Officer

Lee Schalop is a co-founder of Oncoceutics. He held the position of Chief Business Officer since soon after graduating with a doctor of medicine degree from the Albert Einstein College of Medicine in 2008 and was promoted to Chief Operating Officer in 2016. Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities. From 1985 to 1993, he was an investment banker and his fund raising activities included more than 10 initial public offerings, the largest of which raised over $700 million. From 1993 to 2004, he served as a research analyst and authored more than 1,000 reports covering more than 50 different publicly traded companies, earning a reputation for groundbreaking research. Lee is also a director of ImmunoGenes AG, a life sciences company focused on the development of novel antibodies using genetically-modified animals; and sits on the advisory boards of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania, and the New York Chapter of the Juvenile Diabetes Research Foundation, a non-profit dedicated to finding a cure for diabetes and its complications. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences.

Martin Stogniew, Ph.D.

Chief Development Officer

Martin Stogniew brings 33 years of senior executive experience in the pharmaceutical industry and has served as an independent member of the Board of Director for Provid Pharmaceuticals. Dr. Stogniew has made significant contributions resulting in FDA approval of nine New Drug Applications, issuance of 28 US patents, and closure of four major M&A deals valued at $3 billion. Formerly, he was Executive Vice President, Chief Technology Officer of Prestwick Pharmaceuticals and was accountable for all technical and regulatory diligence during the sale of the company to Biovail in 2008. Previously he was Executive Vice President, Scientific Affairs for Vicuron Pharmaceuticals where he played an integral part in the 2005 sale to Pfizer for $1.9B. He was Vice President, Pharmaceutical Sciences for U.S. Bioscience, where he played a key role in the sale to Medimmune. Dr. Stogniew completed a postdoctoral fellowship at The Johns Hopkins University, School of Medicine, earned a Ph.D. in Medicinal Chemistry from the University of Maryland and received a BS in Pharmacy with honors from the University of Maryland. He started with Oncoceutics in 2012.


Joshua Allen, Ph.D.

Senior Vice President, Research and Development

Joshua Allen discovered ONC201 and co-invented the imipridone class of compounds. He directed the preclinical studies that identified ONC201 as an anti-cancer agent, defined its preclinical profile, elucidated its novel mechanism of action, and extended its pharmacophore into a new class of therapies. Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship in pharmacology at the Penn State Cancer Institute. Dr. Allen has authored several research publications and awarded grants for preclinical and clinical development of novel therapies and biomarkers. Several awards have recognized his entrepreneurial research and development efforts in different areas of oncology, including recognition on the 2016 Forbes 30 under 30 list. Dr. Allen joined Oncoceutics in 2012.